In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galectin Therapeutics Inc.

www.galectintherapeutics.com

Latest From Galectin Therapeutics Inc.

Finance Watch: Three New Biopharma IPOs In The US With Eight More Entering The Queue

Public Company Edition: IPO performance has been mixed in 2019, but May has been the busiest month this year. Also, Insmed leads recent follow-on offerings and Dynavax restructures.

Financing Business Strategies

NASH Drug Development Guidance Encourages Sponsors To Adopt Innovative Trial Designs

Although guidance appears to be free of surprises, US FDA once again made a push for sponsors to adopt seamless trial designs.
Clinical Trials Liver & Hepatic

Galectin Plans To Head Into NASH Pivotal Studies Without Biopsy-Evaluated Endpoint

Company is moving its galectin-3 inhibitor into Phase III in non-alcoholic steatohepatitis patients with cirrhosis – a very advanced disease setting – and also to validate endpoints that don’t require liver biopsy.

Clinical Trials Liver & Hepatic

Pipeline Watch: Phase III Studies of CSL112 And RT-100 Imminent

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Hepatic (Liver)
  • Alias(es)
  • Pro-Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Galectin Therapeutics Inc.
  • Senior Management
  • Harold H Shlevin, PhD, Pres. & CEO
    Jack W Callicutt, CFO
  • Contact Info
  • Galectin Therapeutics Inc.
    Phone: (678) 620-3186
    4960 Peachtree Industrial Blvd.
    Ste. 240
    Norcross, GA 30071
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register